The FDA-approved vasodilator that became the world's most popular hair regrowth treatment. Topical application increases blood flow to hair follicles, extending the anagen growth phase. Works for both men and women.
Minoxidil was originally developed as an oral antihypertensive agent. During clinical trials, researchers noticed an unexpected side effect: significant hair growth. This led to its reformulation as a topical solution and eventual FDA approval for male and female pattern hair loss.
Oral minoxidil achieves excellent bioavailability (95% absorption) from the GI tract. Peak plasma levels occur at ~1 hour, but the hair-regrowth effect lasts 24+ hours due to active sulfate metabolite accumulation in hair follicles. Metabolism occurs hepatically via sulfotransferase to the active minoxidil sulfate form—this enzymatic conversion is essential for efficacy.
| Bioavailability | ~95% (oral) — well absorbed |
| Tmax (time to peak) | 1 hour |
| Elimination half-life | 4.2 hours (serum), but hair effect lasts 24h+ |
| Duration of action | 24+ hours (due to active metabolite in hair follicles) |
| Volume of distribution | Large — distributes extensively to skin and hair follicles |
| Protein binding | Negligible — minimal plasma protein binding |
| Metabolism | Hepatic: Sulfotransferase converts minoxidil → minoxidil sulfate (ACTIVE form). Without sulfotransferase activity, drug is ineffective. |
| Active metabolite | Minoxidil sulfate (the actual vasodilator and hair growth stimulator) |
| Excretion | Renal ~90% (primarily as metabolites). Minimal unchanged minoxidil in urine. |
| Food effect | Minimal food effect on absorption. Can take with or without meals. |
Low-dose oral minoxidil for hair loss uses 2.5–5mg daily (much lower than cardiovascular hypertension doses). Women typically start 2.5mg daily; men 5mg daily. Once-daily dosing is standard. Effects visible at 3–6 months. Initial shedding (weeks 2–8) is expected and indicates growth phase synchronization.
Oral minoxidil for hair loss is newer than topical (FDA-approved for hypertension only, not hair loss), but emerging clinical evidence demonstrates superiority to topical formulations. Studies show rapid onset, consistent efficacy, and durable regrowth.
Oral minoxidil's side effect profile at low doses (2.5–5mg) is favorable. Most effects are mild and reversible. The main safety consideration is blood pressure monitoring, as minoxidil is a vasodilator (though systemic effects at hair loss doses are minimal).
Minoxidil is not a CYP450 substrate, so pharmacokinetic interactions are minimal. However, as a vasodilator, it has important pharmacodynamic interactions with antihypertensive medications and NSAIDs that can reduce efficacy.
Minoxidil is available OTC, but our doctors can provide personalized guidance on application, expected timeline, and combination therapies to maximize results.